Cargando…

Therapeutic drug monitoring in dermatology: the way towards dose optimization of secukinumab in chronic plaque psoriasis

BACKGROUND: Despite the favourable efficacy profile of secukinumab, clinicians encounter varying clinical responses among patients potentially associated with under‐ and overdosing. As biologics are expensive, their rational use is crucial and evident. Therapeutic drug monitoring could guide clinici...

Descripción completa

Detalles Bibliográficos
Autores principales:	Soenen, Rani, Wang, Zhigang, Grine, Lynda, Dreesen, Erwin, Schots, Lisa, Brouwers, Els, Declerck, Paul, Thomas, Debby, Lambert, Jo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9320967/ https://www.ncbi.nlm.nih.gov/pubmed/35245966 http://dx.doi.org/10.1111/ced.15157

Ejemplares similares

Secukinumab in the Treatment of Plaque Psoriasis in Patients with Malignancy
por: Gambardella, Alessio
Publicado: (2019)

Assessment of serum biomarkers in patients with plaque psoriasis on secukinumab
por: Morita, Akimichi, et al.
Publicado: (2020)

Efficacy of Secukinumab for Plaque Psoriasis in a Patient on Hemodialysis
por: Ikuma, Daiuske, et al.
Publicado: (2019)

Position Statement on Secukinumab in the Management of Plaque Psoriasis: The Malaysian Perspective
por: Johar, Asmah, et al.
Publicado: (2019)

Effects of secukinumab on metabolic and liver parameters in plaque psoriasis patients
por: Gerdes, S., et al.
Publicado: (2019)

Efficacy and Safety of Secukinumab in Patients with Plaque Psoriasis and Latent Tuberculosis
por: Ribero, Simone, et al.
Publicado: (2019)

Secukinumab: A Review in Moderate to Severe Pediatric Plaque Psoriasis
por: Blair, Hannah A.
Publicado: (2021)

Alopecia Areata After Initiation of Secukinumab Therapy for Plaque Psoriasis
por: Choi, Esther, et al.
Publicado: (2023)

Efficacy and Safety of Secukinumab in Chronic Plaque Psoriasis and Psoriatic Arthritis Therapy
por: Gisondi, Paolo, et al.
Publicado: (2014)

Treatment challenges in the management of moderate-to-severe plaque psoriasis – role of secukinumab
por: Malakouti, Mona, et al.
Publicado: (2016)

Widespread Superficial Dermatophytosis in Patient on Secukinumab for Treatment of Chronic Plaque Psoriasis
por: Neema, Shekhar, et al.
Publicado: (2019)

Correction to: Secukinumab: A Review in Moderate to Severe Pediatric Plaque Psoriasis
por: Blair, Hannah A.
Publicado: (2021)

Successful secukinumab treatment in focal segmental glomerulosclerosis associated with plaque psoriasis
por: Cao, Zhiqiang, et al.
Publicado: (2022)

Effects of adalimumab and secukinumab on comorbidities associated with metabolism in patients with plaque psoriasis
por: Zhang, Si, et al.
Publicado: (2022)

Dyshidrotic eczema in two patients on secukinumab for plaque psoriasis: A case report
por: Bose, Reetesh, et al.
Publicado: (2020)

Secukinumab for Recalcitrant Chronic Plaque Psoriasis in a 9 Year Old Child
por: Shruthi, R, et al.
Publicado: (2021)

Transcriptomic Profiling of Plaque Psoriasis and Cutaneous T-Cell Subsets during Treatment with Secukinumab
por: Liu, Jared, et al.
Publicado: (2021)

Effects of secukinumab and adalimumab on serum uric acid level in patients with plaque psoriasis
por: Zhao, Zheng, et al.
Publicado: (2022)

Dermatology Life Quality Index in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Brodalumab or Ustekinumab
por: Lambert, Jo, et al.
Publicado: (2021)

Secukinumab treatment showed improved quality of life in patients with chronic plaque psoriasis in Australia: Results from the HOPE study
por: Foley, Peter, et al.
Publicado: (2022)

Cost effectiveness of ixekizumab versus secukinumab in the treatment of moderate-to-severe plaque psoriasis in Spain
por: Johansson, Erin, et al.
Publicado: (2018)

Burden of Moderate-to-Severe Plaque Psoriasis and New Therapeutic Approaches (Secukinumab): An Italian Perspective
por: Mantovani, Lorenzo, et al.
Publicado: (2016)

Comparative efficacy of secukinumab against adalimumab and infliximab in patients with moderate-to-severe plaque psoriasis
por: Pan, Ran, et al.
Publicado: (2022)

Secukinumab in Generalized Pustular Psoriasis
por: Madanagobalane, Shraddha
Publicado: (2018)

Promising Tools to Facilitate the Implementation of TDM of Biologics in Clinical Practice
por: Soenen, Rani, et al.
Publicado: (2022)

Secukinumab without the initial loading dose in the treatment of plaque‐type psoriasis – a simplified dosing regimen at the expense of efficacy?
por: Aichelburg, M.C., et al.
Publicado: (2019)

Dose reduction of the new generation biologics (IL-17 and IL-23 inhibitors) in psoriasis: study protocol for an international, pragmatic, multicenter, randomized, controlled, non-inferiority study—the BeNeBio study
por: van der Schoot, Lara S., et al.
Publicado: (2021)

Successful secukinumab therapy in plaque psoriasis is associated with altered gut microbiota and related functional changes
por: Du, Xueshan, et al.
Publicado: (2023)

Real-World Satisfaction with Secukinumab in Clearing the Skin of Patients with Plaque Psoriasis through 24 Months of Follow-Up: Results from US Dermatology Electronic Medical Records
por: Armstrong, April W., et al.
Publicado: (2021)

Successful use of secukinumab in pustular psoriasis
por: Yeung, Jensen, et al.
Publicado: (2016)

Diagnostic and therapeutic guidelines for plaque psoriasis - Brazilian Society of Dermatology
por: Arnone, Marcelo, et al.
Publicado: (2019)

Effectiveness and safety of secukinumab in patients with moderate-to-severe plaque psoriasis – a real life retrospective study
por: Galica, Katarzyna, et al.
Publicado: (2020)

The Effects of Modified Intermittent Fasting in Psoriasis (MANGO): Protocol for a Two-Arm Pilot Randomized Controlled Open Cross-over Study
por: Grine, Lynda, et al.
Publicado: (2022)

Secukinumab is Superior to Ustekinumab in Clearing Skin in Patients with Moderate to Severe Plaque Psoriasis (16-Week CLARITY Results)
por: Bagel, Jerry, et al.
Publicado: (2018)

Effectiveness and safety of secukinumab in Chinese patients with plaque psoriasis in a clinical practice setting: a pilot study
por: Zhu, Si-Man, et al.
Publicado: (2020)

Efficacy and safety of secukinumab in Chinese patients with moderate-to-severe plaque psoriasis: a real-life cohort study
por: Zhao, Yan, et al.
Publicado: (2021)

Treatment with secukinumab for plaque psoriasis in patients with infectious comorbidities and latent tuberculosis: A multi‐case report analysis
por: Fiorella, Carmen
Publicado: (2022)

Profile of secukinumab in the treatment of psoriasis: current perspectives
por: Roman, Michael, et al.
Publicado: (2015)

Secukinumab in the treatment of psoriasis: patient selection and perspectives
por: Yang, Eric J, et al.
Publicado: (2018)

Gradually increasing the dosing interval of Secukinumab for moderate to severe plaque psoriasis: A single‐center, uncontrolled, prospective study in 36 weeks
por: Chen, Xi‐Bei, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_lsvl5tlu4lq5qvpd1dr93rr6u8